Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Short Interest Up 14.7% in October

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest totalling 3,430,000 shares, an increase of 14.7% from the September 30th total of 2,990,000 shares. Based on an average daily volume of 165,700 shares, the short-interest ratio is currently 20.7 days. Currently, 17.4% of the company's shares are short sold.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. HC Wainwright reiterated a "buy" rating and set a $27.00 price objective on shares of Enanta Pharmaceuticals in a report on Thursday, October 10th. JPMorgan Chase & Co. decreased their price target on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an "underweight" rating for the company in a research note on Tuesday, August 6th. Evercore ISI upgraded Enanta Pharmaceuticals to a "strong-buy" rating in a report on Tuesday, August 6th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $22.00 target price on shares of Enanta Pharmaceuticals in a report on Wednesday, October 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $20.00.

Enanta Pharmaceuticals Stock Down 0.7 %

Shares of NASDAQ ENTA traded down $0.08 during midday trading on Tuesday, reaching $11.50. 114,356 shares of the company's stock traded hands, compared to its average volume of 203,147. The company has a market cap of $243.56 million, a price-to-earnings ratio of -1.82 and a beta of 0.58. The stock's 50 day simple moving average is $11.84 and its 200-day simple moving average is $12.83. Enanta Pharmaceuticals has a one year low of $8.08 and a one year high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last announced its earnings results on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.43) by $0.36. Enanta Pharmaceuticals had a negative return on equity of 63.75% and a negative net margin of 160.27%. The business had revenue of $17.97 million for the quarter, compared to analysts' expectations of $17.44 million. During the same quarter last year, the firm earned ($1.27) EPS. The business's revenue for the quarter was down 4.9% on a year-over-year basis. Equities analysts predict that Enanta Pharmaceuticals will post -5.3 EPS for the current fiscal year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC bought a new stake in shares of Enanta Pharmaceuticals in the 2nd quarter valued at about $35,000. US Bancorp DE boosted its stake in Enanta Pharmaceuticals by 4,933.7% in the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company's stock valued at $45,000 after acquiring an additional 4,243 shares in the last quarter. State Board of Administration of Florida Retirement System purchased a new position in Enanta Pharmaceuticals in the first quarter worth $118,000. Quest Partners LLC increased its position in shares of Enanta Pharmaceuticals by 511.2% during the second quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company's stock worth $150,000 after purchasing an additional 9,692 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Enanta Pharmaceuticals during the first quarter worth $191,000. Hedge funds and other institutional investors own 94.99% of the company's stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.